Page 1

AdAlta next generation protein therapeutics 14 October 2021 ASX Announcement QUARTERLY CASH FLOW STATEMENT - SEPTEMBER QUARTER 2021 Quarter highlights • • • • • • Strong $ 6.77 million cash position at 30 September 2021 ( $ 5.79 million at 30 June 2021 ) Development of inhaled version of AD - 214 progressing for next clinical trial $ 0.76 million BTB funds transferred to AD - 214 inhalation program Further positive pre - clinical data for AD - 214 in kidney fibrosis Collaboration established with Carina Biotech to create precision engineered , i - body enabled CAR - T cell therapies Discovery research commenced on our second GPCR target implicated in fibrotic disease Secured $ 4.0 million non - dilutive finance facility with Victorian Government MELBOURNE Australia , 14 October 2021 : AdAlta Limited ( ASX : 1AD ) , the clinical stage drug discovery company developing novel therapeutic products from its i - body platform reports significant pipeline expansion and progress during the September quarter , which ended with an improved cash balance of $ 6.77 million . Reflecting on progress in the quarter , AdAlta's CEO and Managing Director , Dr Tim Oldham commented : “ In the first quarter of FY22 AdAlta achieved significant pipeline expansion milestones and an improved cash position . Building on the findings of our Phase I clinical trial and preclinical PET imaging program , development of a more cost effective and patient convenient inhaled formulation for use in our next clinical trials is underway . We are pleased to be able to reallocate BTB grant funding for this . We also reported positive new pre - clinical data for AD - 214 in a mouse model of kidney fibrosis and we expanded our fibrosis / inflammation portfolio by initiating discovery against a new target . Separately , we were delighted to establish a collaboration with Carina Biotech to develop precision engineered , i - body enabled CAR - T cell therapies to offer new hope to patients with cancer . Under the collaboration we will develop i - body enabled monospecific , bispecific and dual CAR - T products against five targets . This represents our second program in the fast - growing immuno - oncology field . " A. Operations overview 1. Fibrosis assets i . AD - 214 AdAlta is developing its lead product , AD - 214 , as a first in class , next generation antibody therapeutic for the treatment of Idiopathic Pulmonary Fibrosis ( IPF ) and Interstitial Lung Disease ( ILD ) with potential in other fibrotic diseases and cancer . The results of the Phase I clinical trial of AD - 214 in healthy volunteers and of pre - clinical PET imaging studies of radiolabelled AD - 214 ( RL - AD - 214 ) were reported in July and detailed in the previous quarterly report . Briefly , intravenous AD - 214 clearly engaged its